Anthony Howard Goldstone

Anthony Howard Goldstone's AcademicInfluence.com Rankings

Philosophy

#8537

World Rank

#11943

Historical Rank

Logic

#5567

World Rank

#6975

Historical Rank

philosophy Degrees

Anthony Howard Goldstone

Biology

#11577

World Rank

#14981

Historical Rank

Genetics

#1251

World Rank

#1353

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Anthony Howard Goldstone Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Anthony Howard Goldstone's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Acute myeloid leukemia. (2002) (3265)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. (2010) (1676)
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial (1993) (1017)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial (2002) (1003)
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (1987) (776)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. (2007) (734)
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin (2006) (706)
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. (2005) (684)
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients (1996) (636)
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. (2005) (598)
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. (2011) (596)
Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial (1998) (577)
A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment (2007) (573)
A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial (1999) (444)
Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. (1999) (424)
Hepatitis B transmission from contaminated cryopreservation tank (1995) (419)
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers (2007) (405)
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. (2002) (398)
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. (2002) (362)
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. (2002) (361)
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial (2002) (338)
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). (2009) (327)
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 (2010) (322)
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. (2014) (301)
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. (2004) (289)
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation (2005) (273)
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. (2009) (265)
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. (2002) (263)
Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials (2007) (259)
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials (2009) (233)
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. (2005) (226)
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. (2004) (222)
Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. (1996) (218)
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. (2010) (211)
Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. (1992) (201)
Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia (2004) (200)
Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. (2002) (195)
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. (2006) (193)
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. (2003) (188)
Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries (2003) (168)
Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. (2013) (167)
Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT (1999) (162)
Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single‐centre experience of 133 episodes in 116 patients (1994) (161)
Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. (2009) (160)
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial (2012) (160)
Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. (1997) (158)
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. (2003) (157)
Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. (1997) (149)
High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Blood and Marrow Transplantation (1999) (147)
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial (2009) (139)
Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. (1989) (137)
Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. (1996) (136)
Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 (2010) (133)
Establishing the presence of the t( 15; 17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial (1996) (133)
WT1 mutations in T-ALL. (2009) (127)
Interferon‐alpha up‐regulates bcl‐2 expression and protects B‐CLL cells from apoptosis in vitro and in vivo (1994) (122)
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. (2002) (122)
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. (2003) (119)
Low‐dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma (2005) (118)
A UK multicentre phase II study of rituximab (chimaeric anti‐CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response (2000) (115)
REMISSION INDUCTION WITH ADENOSINE-DEAMINASE INHIBITOR 2'-DEOXYCOFORMYCIN IN THY-LYMPHOBLASTIC LEUKÆMIA (1980) (110)
Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party (1993) (110)
Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes (2007) (109)
High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. (2008) (108)
Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials (1997) (108)
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. (2013) (107)
IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. (2012) (107)
Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. (1996) (106)
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. (2011) (105)
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. (2007) (105)
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. (2009) (103)
ALPHA-INTERFERON THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA (1988) (102)
Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation (2008) (101)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2008) (98)
Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. (2004) (98)
Cell sorter analysis of leukaemia-associated antigens on human myeloid precursors (1978) (96)
TEL‐AML1 fusion in acute lymphoblastic leukaemia of adults (1996) (96)
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. (2003) (92)
Frequency of CBFβ/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials (1997) (88)
Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). (1996) (86)
The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. (2006) (84)
Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortality (2002) (83)
Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow T (1997) (82)
Hepatitis B nucleotide sequence analysis: linking an outbreak of acute hepatitis B to contamination of a cryopreservation tank. (1996) (79)
G‐CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial (1997) (78)
Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT) (1999) (77)
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. (2010) (77)
IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. (2014) (75)
High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. (1994) (69)
Mini‐BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease (1992) (68)
Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non‐Hodgkin's lymphoma (1985) (68)
Plasmapheresis in systemic lupus erythematosus. (1977) (67)
Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. (1994) (65)
Extended routine polymerase chain reaction surveillance and pre‐emptive antiviral therapy for cytomegalovirus after allogeneic transplantation (2000) (63)
High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. (1999) (60)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation (2016) (58)
Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. (2010) (58)
Autologous bone marrow transplants: Different indications in Europe and North America (1989) (57)
Conventional second‐line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first‐line salvage therapy regimens (2005) (56)
Appearance of anti-DNA antibodies in patients treated with interferon-alpha. (1993) (54)
Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. (2003) (54)
Frequency of clonal remission in acute myeloid leukaemia (1993) (53)
Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry. (1994) (53)
Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning (2013) (52)
T‐ and B‐cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T‐cell‐depleted, reduced‐intensity allogeneic stem cell transplantation with an alemtuzumab‐containing conditioning regimen followed by escalated donor lymphocyte infusions (2003) (51)
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2008) (50)
The significance of host haemopoietic cells detected by cytogenetic analysis of bone marrow from recipients of bone marrow transplants (1986) (49)
New Evidence Relating to the Nature and Origin of the Hairy Cell of Leukaemic Reticuloendotheliosis (1977) (48)
Plasma exchange in systemic lupus erythematosus. (1981) (48)
FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. (1997) (48)
Granulocyte-macrophage colony-stimulating factor may inhibit neutrophil migration in vivo. (1989) (47)
Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party. (1999) (46)
Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. (1997) (46)
Randomized placebo‐controlled trial of granulocyte colony stimulating factor (G‐CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party (2009) (45)
A prospective randomized study of prophylactic teicoplanin to prevent early Hickman catheter‐related sepsis in patients receiving intensive chemotherapy for haematological malignancies (1993) (45)
Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia (2008) (44)
UKALLXII / ECOG 2993 : addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia (2014) (43)
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial (2013) (42)
Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT. (1994) (42)
IgA and IgM cytoplastic inclusions in a series of cases of chronic lymphocytic leukaemia. (1976) (41)
Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies (2014) (41)
Del (9q) AML: clinical and cytological characteristics and prognostic implications (2005) (41)
Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial. (2007) (41)
Demonstration of developing myelodysplasia/acute myeloid leukaemia in haematologically normal patients after high‐dose chemotherapy and autologous bone marrow transplantation using X‐chromosome inactivation patterns (1996) (41)
Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia‐negative peripheral blood stem cells (1997) (39)
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation (2004) (39)
Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. (1993) (36)
The effect of gastric antigens on the in vitro migration of leucocytes from patients with atrophic gastritis and pernicious anaemia. (1973) (36)
High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party. (1994) (35)
Use of 18F‐FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions (2005) (35)
Immunological parameters in the aged and in Alzheimer's disease. (1982) (34)
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission (2009) (34)
Risk‐stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia (2013) (34)
How I treat acute lymphocytic leukemia in adults. (2007) (34)
Rituximab in combination with CODOX‐M/IVAC: a retrospective analysis of 23 cases of non‐HIV related B‐cell non‐Hodgkin lymphoma with proliferation index >95% (2011) (32)
Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial (2010) (31)
Influence of computer-aided detection false-positives on reader performance and diagnostic confidence for CT colonography. (2009) (31)
Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia — a phase II study (2005) (31)
Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial. (2009) (31)
HTV-2-ASSOCIATED AIDS IN THE 1970s (1988) (30)
Recombinant interferon alfa 2 a in the treatment of patients with early stage B chronic lymphocytic leukaemia (1993) (30)
Molecular Classification Improves Risk Assessment in Adult BCR-ABL1-negative B-ALL. (2021) (28)
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure (2014) (27)
Does Imatinib Change the Outcome in Philapdelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study. (2007) (26)
PHA responsiveness and subpopulations of circulating lymphocytes in pernicious anemia. (1974) (25)
Transplantation in adult ALL. (2009) (25)
ABC of clinical haematology: The acute leukaemias (1997) (25)
Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation. (1995) (24)
A prospective randomized study of prophylactic teicoplanin to prevent early Hickman catheter-related sepsis in patients receiving intensive chemotherapy for haematological malignancies. (1991) (24)
Distinctive cytoplasmic inclusions in chronic lymphocytic leukaemia. (1975) (24)
Membrane marker analysis of 'lymphoid' and myeloid blast crisis in PH1 positive (chronic myeloid) leukemia. (1977) (24)
Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2′,5′ oligoadenylate system and clinical response (1990) (24)
Combined T and B Cell Acute Lymphoblastic Leukaemia (1974) (24)
Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial. (2004) (23)
High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma : the EBMT experience (1994) (23)
High-dose therapy for diffuse large-cell lymphoma in first remission. (1998) (23)
A Sensitive Risk Score for Directing Treatment in Younger Patients with AML. (2006) (23)
Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cells. (1992) (22)
The macrophage electrophoretic migration test in cancer. (1973) (22)
Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience (2012) (22)
Production of tumour-derived suppressor factor in patients with acute myeloid leukaemia. (1991) (20)
SOHO State of the Art Update and Next Questions: Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia (2018) (20)
Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. (1995) (20)
Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma. (1993) (19)
Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients. (1987) (19)
The value of molecular stratification for CEBPA DM and NPM1 MUT FLT3 WT genotypes in older patients with acute myeloid leukaemia (2015) (19)
Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia (1997) (19)
A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients (1990) (17)
Recombinant alpha-interferons, thyroid irradiation and thyroid disease. (1991) (17)
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft (2007) (17)
Chlorambucil lung toxicity. (1990) (17)
Continuous intravenous infusion of high dose recombinant interleukin 2 for advanced lymphomas--a phase II study. (1991) (16)
Clonal identification in acute lymphoblastic leukemia. (1979) (16)
Measurement of haematological indices of chronic rheumatic disease with two newer generation automated systems, the H1 and H6000 (Technicon). (1991) (16)
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen. (2002) (16)
Long-term results of the MRC AML10 trial. (2006) (16)
Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects (2004) (15)
HLA antigens in pernicious anaemia. (1976) (15)
Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells. (1992) (15)
High‐dose therapy for Hodgkin's disease (1999) (15)
Chronic lymphocytic leukaemia uncovered by successful treatment of acute myeloid leukaemia. (1976) (14)
Bone marrow transplant patients with life-threatening organ failure: when should treatment stop? (1999) (14)
Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring (2000) (13)
The effect of macrophage colony‐stimulating factor on haemopoietic recovery after autologous bone marrow transplantation (1992) (12)
Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial. (2008) (12)
High-dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus (2004) (12)
Serum macrophage colony‐stimulating factor (M‐CSF) levels correlate with clinical response to interferon‐alpha in patients with early‐stage B‐CLL (1994) (12)
Modern trends in bone marrow transplantation for acute myeloid and acute lymphoblastic leukemia (1992) (12)
Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. (1990) (12)
Haematological aspects of systemic lupus erythematosus: a reappraisal using automated methods. (1982) (12)
Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy. (1997) (12)
Transplants in Adult ALL--? Allo for everyone. (2009) (11)
Idarubicin for remission induction of acute myeloid leukemia: United Kingdom multicenter experience. (1993) (11)
Haematological reassessment of rheumatoid arthritis using an automated method. (1986) (11)
The outcome of 551 1(st) CR transplants in adult ALL from the UKALL XII/ECOG 2993 study (2004) (11)
Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias. (2006) (11)
Identification of PML/RARα rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients (2000) (11)
Myeloma in a case of hodgkin's disease. (1974) (11)
Platelet hyperaggregability occurring during prolonged continuous intravenous infusions of prostacyclin analogue ZK 36374 (1985) (11)
Myeloma in mother and daughter. (1973) (10)
WT 1 mutations in TALL (2009) (10)
Electrophoresis of lymphocytes from normal human subjects and patients with chronic lymphocytic leukaemia. (1974) (10)
A comparison of automated cytochemical analysis and conventional methods in the classification of acute leukaemia (1980) (10)
The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial. (1999) (10)
A chronic myeloproliferative disorder associated with monosomy 7 in the bone marrow cells; normal karyotype in acute transformation (1982) (10)
Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient. (1993) (10)
Leukostasis in chronic myeloid leukaemia. (1978) (9)
Response: Chemotherapy or allografting for young adults with high-risk ALL? (2008) (9)
Allogeneic transplantation following failure of autologous transplantation for lymphoma. (1998) (9)
Autologous stem cell transplants in lymphomas. (1996) (9)
Autologous stem cell transplantation remains beneficial for patients relapsing after R‐CHOP chemotherapy and who respond to salvage chemotherapy (2012) (9)
Patients with Lymphoplasmacytic Lymphoma Can Be Salvaged with Autologous Stem Cell Transplantation, Irrespectively of the Number of Previous Treatment Lines. Analysis of 146 Cases from the European Bone Marrow Transplant Registry (EBMT). (2004) (9)
DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL (2017) (9)
Cellular cytotoxic function and potential in acute myelogenous leukaemia. (1991) (9)
Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARα rearrangement in newly diagnosed AML (1999) (9)
Folic acid and the pill. (2009) (9)
Bacterial infections in lymphoma patients treated with recombinant interleukin-2. (1991) (9)
Demonstration of the increase in serine esterase-positive T cells in hairy-cell leukemia patients undergoing alpha-interferon therapy. (1989) (9)
The impact of transplant in AML in 2nd CR: A prospective study of 741 in the MRC AML 10 and 12 Trials [Abstract] (2004) (8)
The role of autologous bone marrow transplantation in the treatment of malignant disease. (1987) (8)
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial (2020) (8)
Reversal of Fludarabine Induced Testicular Damage in a Patient with Chronic Lymphocytic Leukaemia (CLL), by Suppression of Pituitary-Testicular Axis Using Gonadotrophin Releasing Hormone (GnRH) (2001) (8)
Prophylactic teicoplanin during insertion of Hickman catheters (1990) (8)
Letter: Autoimmune haemolytic anaemia in ulcerative colitis. (1974) (8)
High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma. (1999) (8)
Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia. (1990) (8)
Acute promyelocytic leukaemia: further evidence of the differentiation-linked expression of Ia-like (p28,33) antigens on leukaemic cells. (2009) (7)
Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell‐origin of ALL subgroups – a UKALLXII study (2010) (7)
A hemalog D analysis of chronic lymphocytic leukaemia and other lymphoproliferative disorders affecting the blood. (1981) (7)
Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups (2010) (7)
Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion. (1991) (7)
Peripheral blood progenitor cells versus bone marrow. (1994) (7)
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. (2017) (6)
Effect of surgery on monocyte function. (1983) (6)
First remission autologous bone marrow transplantation for Hodgkin's disease--preliminary EBMT data. (1995) (6)
Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the international ALL trial (MRC UKALL-XII/ECOG E2993) (2004) (6)
Teicoplanin and prophylaxis of Hickman catheter insertions. (1992) (6)
Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial. (2005) (6)
Effect of surgery on monocyte function (1982) (6)
Treatment of childhood and adult acute lymphoblastic leukaemia (1997) (6)
Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation. (2009) (6)
Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias (2005) (5)
Acute promyelocytic leukaemia (1994) (5)
Identification of PML/RARalpha rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients. MRC Adult Leukaemia Working Party. (2000) (5)
Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia?: Results from 1666 patients in three MRC trials [Abstract] (2004) (5)
Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL) (2004) (5)
Automated leucocyte differential counts in chronic lymphocytic and hairy-cell leukaemias: a comparison of the Hemalog D, H6000 and Coulter S Plus IV. (1987) (5)
Autologous stem cell transplantation in Hodgkin's disease. (2002) (5)
Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant (2010) (5)
Non-myeloablative allogeneic transplantation for high-risk acute leukemia and myelodysplasia. (2001) (4)
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial (2010) (4)
Automated leucocyte differential counts in acute leukaemia: a comparison of the Hemalog D, H6000 and Coulter S-plus IV. (1986) (4)
Escalating dose donor lymphocyte infusions following non-myeloablative allogeneic transplantation are associated with minimal toxicity with sibling donors but a significant risk of severe GVHD with unrelated donors. (2001) (4)
Development of Squamous Cell Carcinoma of the Skin During Induction Chemotherapy for Acute Myeloid Leukemia (2002) (4)
Conventional allograft and autograft in low grade lymphoma. (2005) (4)
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII (2016) (4)
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial (2022) (4)
Autologous bone marrow transplantation in multiple myeloma: a single centre experience of 23 patients. (1994) (4)
Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL). (2002) (4)
Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of Technique. (1990) (4)
Prognostic factors in older AML patients receiving intensive and non-intensive therapy: Analysis of the UK AML11 and AML14 trials [Abstract] (2005) (4)
Scabies Infestation following Autologous Bone Marrow Transplantation. (1990) (3)
Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma (2011) (3)
The value of molecular monitoring for residual disease (MRD) in early morphological remitters among adults diagnosed with B cell ALL and treated according to the MRC UKALL12 protocol. (2005) (3)
Autologous bone marrow transplantation in solid tumors. (1990) (3)
Increased neutrophil peroxidase activity in acute myeloid leukaemia. (1982) (3)
Acute Lymphoblastic Leukemia: Epidemiology (2011) (3)
An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy (2015) (3)
Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se. (2008) (3)
reconstitution cell transplantation: potential role of Campath-1H in delaying immune High incidence of cytomegalovirus infection after nonmyeloablative stem (2008) (3)
The Allogeneic Effect in Non-Hodgkin's Lymphoma (2003) (3)
Rituximab Does Not Increase the Complication Rate, Particularly Perforation, When Added to Chemotherapy for Patients with Primary B-Cell Lymphomas of the Gastrointestinal Tract. (2005) (3)
Transplants for the old but not for the young?--The enigma of adult ALL. (2011) (3)
Adoptive Cellular Therapy for Cytomegalovirus Following Allogeneic Stem Cell Transplantation: Toxicity and Efficacy. (2004) (3)
Residual T cells in chronic lymphocytic leukaemia. (1973) (3)
Pseudohyponatraemia due to L-asparaginase-associated dyslipidaemia in T-cell lymphoblastic lymphoma (2014) (3)
Bone Marrow Transplantation Versus Chemotherapy in Acute Lymphoblastic Leukemia. Joint Trial of the Medical Research Council (UKALL-12) with the United States Eastern Cooperative Oncology Group E2993 (1997) (2)
EBMT experience of autologous bone marrow transplantation in lymphoma. (1989) (2)
Redefining Transplant in Acute Leukemia (2011) (2)
Double autografting: A potential curative regimen for acute leukemia? (1986) (2)
AUTOLOGOUS STEM CELL TRANSPLANTATION REMAINS BENEFICIAL FOR PATIENTS RELAPSING AFTER R-CHOP AND WHO RESPOND TO SALVAGE CHEMOTHERAPY (2011) (2)
Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen. (2005) (2)
NON-MYELOABLATIVE TRANSPLANTS WITH OR WITHOUT CAMPATH-1H: COMPARISON BETWEEN TWO PROSPECTIVE STUDIES IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS. (2002) (2)
Ring chromosome 6 and i(17q-) in a patient with acute promyelocytic leukemia. Absence of translocation t(15;17). (1988) (2)
High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation. (1994) (2)
The clinical characteristics , therapy and outcome of 85 adults with acute lymphoblastic leukemia and t ( 4 ; 11 ) ( q 21 ; q 23 ) / MLL-AFF 1 prospectively treated on UKALLXII / ECOG (2013) (2)
Non‐Hodgkin Lymphoma (2010) (2)
STUDIES OF CELL SIZE IN LYMPHOPROLIFERATIVE DISORDERS (1980) (2)
Angioimmunoblastic T-Cell Lymphoma: A Large Series Outcome Analysis. (2005) (2)
Management of non-Hodgkin lymphoma in adults in Scandinavia, United Kingdom, and The Netherlands. Report from the European School of Oncology intercity meeting at Huddinge Hospital, 3rd June, 1988. (1989) (2)
Young red cell preparation--a comparison of available methods. (1985) (2)
Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL (2020) (2)
Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection. (1995) (2)
Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy. (1996) (2)
Reduced intensity allogeneic stem cell transplantation in patients with myelofibrosis (2006) (1)
T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies (2008) (1)
Scientific program and abstractDouble autografting: A potential curative regimen for acute leukemia? (1986) (1)
Does Concomitant Methotrexate (MTX) and GM-CSF Administration after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Predispose to Thrombotic Microangiopathy (TMA)?. (2004) (1)
Autologous bone marrow transplantation. (1984) (1)
randomized prospective trial (UKALL XII/ECOG 2993) immunophenotype, cytogenetics, and outcome from the large T-cell acute lymphoblastic leukemia in adults: clinical features, (2013) (1)
Novel Approaches to the Management of Non-Hodgkin Lymphoma (2005) (1)
Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure (2011) (1)
Transplant related septicaemia in patients undergoing autologous bone marrow transplantation for lymphoma and acute leukaemia. (1991) (1)
Leukaemias, lymphomas, and allied disorders: Case studies : the Cambridge experience (1976) (1)
Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993) (2008) (1)
Atypical mycobacterial infection in alpha interferon-treated hairy cell leukaemia. (1988) (1)
Recombinant interferon-alpha 2 antibodies in chronic lymphocytic leukemia. (1994) (1)
Cooperation between United Kingdom and Soviet Union (1991) (1)
Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol. (2005) (1)
Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantation (2004) (1)
Growth Factor Administration in Lymphoma Transplants: Use of Flow Cytochemistry via the H*1 in Predictin Engraftment (1992) (1)
Lymphocyte activation in patients with acute myeloid leukaemia Evidence for the presence of myeloblast antigen? (2005) (1)
Recombinant Interferon-α2 Antibodies in Chronic Lymphocytic Leukemia (1994) (1)
Bone Marrow Transplantation for Non-Hodgkin’s Lymphoma in Europe: The Current Position (1990) (1)
Leukemia Ecology: Ecological Prophylaxis of Leukemia (1984) (1)
Molecular monitoring of residual disease (MRD) during induction and intensification phases in low risk adult B cell ALL treated according to the MRC UKALL12 protocol. (2005) (1)
Aetiology and Management of Non‐Hodgkin's Lymphoma (2007) (1)
lymphoblastic leukemia regimen enhances long-term outcomes in Philadelphia positive acute UKALLXII/ECOG2993: addition of imatinib to a standard treatment (2014) (1)
Therapiestrategien bei malignen Lymphomen (1995) (1)
Book Review: Clinics in Haematology, Vol 9 No. 1: Cytogenetics and Haematology (1980) (0)
Role of Allogeneic Stem Cell Transplantation in Lymphoplasmacytic Lymphoma. Analysis of 61 Cases from the European Bone Marrow Registry (EBMT). (2004) (0)
Plasma exchange insystemic lupus erythematosus (1981) (0)
Wilsede-Schule für Onkologie und Hämatologie – Wilsede School for Oncology and Hematology (1995) (0)
Systemic Irradiation Myelomatosis-The Therapy of (1990) (0)
Atypical Surface Marker Characteristics in a T-Cell Lymphoma (2009) (0)
Pernicious Anemia PHA Responsiveness and Subpopulations of Circulating Lymphocytes in (2011) (0)
Acute lymphoblastic leukaemia. (1975) (0)
Antimicrobial use in febrile neutropenia — The reality (1998) (0)
Retinoic Acid: Result of the Randomized MRC Trial All-Trans Predict Prognosis in Acute Promyelocytic Leukemia Treated With Presenting White Blood Cell Count and Kinetics of Molecular Remission (2013) (0)
A unique case of three autografts for acute myelogenous leukaemia with subsequent long term survival in second remission. (1991) (0)
Molecular monitoring of minimal residual disease in adult ALL, the UKALL12 trial experience (2006) (0)
Application of anti-ALL serum and other cell markers for leukaemia diagnosis and analysis of human stem cells. (1978) (0)
Reply to C. Fozza. (2013) (0)
Brief an die Herausgeber · Letter to the Editors (2009) (0)
High-Dose Therapy for the Malignant Lymphomas (1995) (0)
Issues of Consent and Side-Effects of Treatment for Haematological Malignancies (1999) (0)
Identification of a common source outbreak of hepatitis B infection in a bone marrow transplant facility by nucleotide sequence analysis. (1996) (0)
Radionuclide Tracer Techniques in Haematology (1982) (0)
Subject Index, Vol. 67, 1982 (2004) (0)
Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) (2010) (0)
Teicoplanin in gram-positive infections : an approach for the nineties? : proceedings of a satellite symposium to the 24th congress of the International Society of Haematology held 23 August 1992 in London (1993) (0)
Chronic Granulocytic Leukaemia in Plasma Erythropoietin Values in Patients Pregnancy with Renal Failure (0)
Management of Non-Hodgkin’s Lymphomas in Adults in Scandinavia, the United Kingdom and the Netherlands: Conclusions of the Fourth Intercity Meeting, 1988 (1990) (0)
lymphoproliferative disorders comparison between 2 prospective studies in patients with Nonmyeloablative transplantation with or without alemtuzumab (2013) (0)
Bone marrow transplantation in malignant lymphoma. Report of a workshop at the third international conference in lymphoma at Lugano, Switzerland, June 1987 (1987) (0)
Proceedings: The development of myelomatosis in a case of existing Hodgkin's disease. (1974) (0)
Bone marrow transplantation. (1990) (0)
How Does Autografting Cure Aggressive Malignant Non-Hodgkin’s Lymphoma? (2020) (0)
Molecular characterization of the chromosome 9q deletion in AML. (2000) (0)
Outcome of allogeneic stem cell transplantation in adults with high-risk myeloid malignancies using an alemtuzemab based reduced-intensity-conditioning regimen (2004) (0)
24. Contribution of 18F-FDG PET to staging after reduced intensity allogeneic stem cell transplantation for Hodgkin and NHL (2003) (0)
Etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP) can cytoreduce resistant myeloma patients and mobilise them for transplant without adverse effects. (2003) (0)
Contents, Vol. 67, 1982 (1982) (0)
5 year experience of intensive care for critically ill patients following chemotherapy or bone marrow transplantation: Who should go to ICU? (2001) (0)
Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL (2015) (0)
Role o f N onmyeloablative A llogeneic S tem-Cell Transplantation A fter F ailure o f A utologous Transplantation i n P atients W ith L ymphoproliferat ive Malignancies (2002) (0)
The role of PET scanning in directing immune manipulations following reduced intensity transplants in adults with lymphoid malignancies. (2004) (0)
New Drugs for Lung Cancer (2017) (0)
Measurementofhaematological indices ofchronic rheumatic disease withtwo newer generation automated systems, theHiandH6000(Technicon) (1991) (0)
The use of PET scans to direct immunotherapy following reduced intensity stem cell transplants in adults with lymphoid malignancies (2005) (0)
Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol (2008) (0)
cytometry. IV. CD34 overexpression in acute myelogenous leukemia Leukemia-associated changes identified by quantitative flow (2011) (0)
(ALL); an MRC UKALL12/ECOG 2993 study Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (2012) (0)
Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT) (2014) (0)
Transplantation study from the European Group for Blood and Marrow transplantation in multiple myeloma: a retrospective case-matched Allogeneic bone marrow transplantation versus autologous stem cell (2011) (0)
Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma (2011) (0)
The impact of imatinib therapy on adult Philadelphia positive acute lymphoblastic leukaemia (ALL): Early results from the UKALL12/ECOG 2993 study (2005) (0)
Allogeneic stem cell transplantation for high-risk acute myeloid leukemia: No increase in relapse with alemtuzumab-depleted grafts. (2005) (0)
Intensive therapy and hematopoietic stem cell rescue in lymphoma: Summary of the Keystone Lymphoma Workshop (1995) (0)
Blood and Bone Marrow Transplantation analysis from the Lymphoma Working Party of the European Group for an following reduced intensity allogeneic progenitor cell transplantation: Chemoresistant or aggressive lymphoma predicts for a poor outcome (2013) (0)
Uses of Cancer Data (2005) (0)
Haematology 1: Leukaemias. J. M. Goldman and H. D. Preisler (Eds). Butterworths, London, 1984. No. of pages: 384 Price: £29.00 (1985) (0)
Kongressbericht – Congress Report (1995) (0)
Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study (2012) (0)
University of An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation (2017) (0)
Transplantations in adult acute lymphoblastic leukemia--grounds for optimism? (2009) (0)
Is There Evidence for a Graft Versus Leukemia Effect in Adult ALL ? (2009) (0)
Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients (2015) (0)
Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma. (1995) (0)
Late Events in Patients with Relapsed or Refractory Hodgkin’s Lymphoma Treated with an Autologous Stem Cell Transplantation. (2007) (0)
Sequential quantitative minimal residual disease in BCR-ABL positive acute lymphoblastic leukaemia: Differential observations between major and minor fusion gene rearrangements and variation due to source material (2004) (0)
Bone M arrow T ransplant P atients W ith L ife-Threatening Organ F ailure: W hen S hould T reatment S top? (1999) (0)
Acute Promyelocytic Leukemia Characterization of Cryptic Rearrangements and Variant Translocations in (2013) (0)
A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically Ill Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Anthony Howard Goldstone?

Anthony Howard Goldstone is affiliated with the following schools:

Anthony Howard Goldstone's Academic­Influence.com Rankings

Why Is Anthony Howard Goldstone Influential?

Anthony Howard Goldstone's Published Works

Published Works

What Schools Are Affiliated With Anthony Howard Goldstone?

Anthony Howard Goldstone's AcademicInfluence.com Rankings